Individualized Neuromuscular Quality of Life Questionnaire

Abstract

The Individualized Neuromuscular Quality of Life Questionnaire (INQoL) is a specialized, patient-reported outcome measure designed to assess the health-related quality of life (HRQoL) specifically in individuals suffering from neuromuscular disorders (NMDs). This comprehensive instrument consists of 45 items structured across three primary domains: symptom burden, impact on specific life domains (functional limitations and social effects), and the effects of treatment. The scale utilizes a scoring system where a higher total score corresponds directly to a greater negative impact on the patient’s quality of life, signifying increased disability and distress resulting from the condition.

Keywords

INQoL, Neuromuscular disorders, Quality of life, HRQoL, Patient-Reported Outcome (PRO), Symptom assessment, Functional status, Health status, Musculoskeletal.

Authors

Rose M, et al. (2006); Dutch version: Seesing FM, et al. (2015)

Purpose

The primary purpose of the INQoL is to provide a robust and disease-specific measure of health-related quality of life (HRQoL) for patients diagnosed with various neuromuscular disorders. Prior to its development, existing generic quality of life measures often failed to capture the unique and specific challenges, symptom profiles, and functional limitations inherent to NMDs, such as muscle weakness, fatigue, and pain.

The questionnaire is intended for use in both clinical practice and research settings. In clinical settings, it helps clinicians monitor disease progression, evaluate the effectiveness of interventions (pharmacological or rehabilitative), and facilitate patient-physician communication regarding the patient’s subjective experience. In research, the INQoL serves as a critical outcome measure for clinical trials involving new treatments for NMDs.

Construct

The INQoL measures the multidimensional construct of health-related Quality of Life (HRQoL) as experienced by individuals living with chronic neuromuscular conditions. This construct is operationalized through 45 items distributed across three core domains, ensuring a comprehensive assessment that extends beyond mere physical function:

• Symptom Burden: Items relating to the frequency, severity, and distress caused by physical symptoms common in NMDs, such as muscle pain, fatigue, and weakness.
• Impact on Life Domains: Items assessing the functional and psychosocial consequences of the disorder, covering daily activities, social participation, interpersonal interactions, and emotional well-being.
• Treatment Effects: Items focusing on the perceived positive or negative effects, side effects, and burden associated with ongoing treatments or disease management strategies.

By assessing these specific domains, the INQoL offers a nuanced view of HRQoL that is highly relevant to the patient population, improving upon the sensitivity and specificity of generic QoL instruments.

Validity

The validation process for the INQoL, essential for its application in psychometrics, typically involves thorough testing to ensure the instrument measures what it intends to measure.

• Content Validity: The initial development of the INQoL involved extensive input from patients with various NMDs and clinical experts, ensuring that the 45 items comprehensively cover all aspects of HRQoL relevant to the population, including sensory functions and pain, personal factors, and interpersonal relationships.
• Construct Validity: Studies have demonstrated strong correlations between the INQoL scores and scores from other established measures of HRQoL (e.g., SF-36) and disease severity indices (e.g., muscle strength measures), indicating that the scale accurately reflects the theoretical construct of disease-specific QoL impairment.
• Known-Groups Validity: The INQoL has been shown to successfully differentiate between groups of patients categorized by varying levels of disease severity (e.g., mild versus severe functional impairment), further supporting its clinical utility and validity.

Reliability

Reliability studies confirm the consistency and stability of the INQoL scores across different administrations and within its own structure.

• Internal consistency: High internal consistency has been reported for the overall scale and its three primary domains, typically demonstrated by Cronbach’s alpha values exceeding the acceptable threshold of 0.70. This suggests that the items within each domain are highly interrelated and measure the same underlying construct.
• Test-Retest Reliability: The stability of the scale over time, assuming the patient’s clinical status remains unchanged, is confirmed by test-retest reliability studies, typically yielding high intraclass correlation coefficients (ICCs). This ensures the scale is stable and reliable for longitudinal monitoring in clinical trials.

Factor Analysis

Factor analysis is crucial for confirming the structural integrity of the INQoL. Given the scale’s design, confirmatory factor analysis (CFA) is employed to validate the hypothesized three-factor structure (Symptoms, Impact on Life Domains, and Treatment Effects).

Initial studies by the developers supported the multidimensional structure, indicating that the 45 items load appropriately onto the three distinct yet correlated factors. This structural validation ensures that subscale scores can be interpreted independently and that the overall total score provides a reliable summary of the general impairment of quality of life due to the neuromuscular condition.

Instrument

Test Type: Questionnaire (Patient-Reported Outcome Measure)

Format: 45 items distributed across three domains: Symptoms, Impact, and Treatment Effects.

Language Available: Original English, Dutch version (Seesing FM, et al., 2015), and likely other translations.

Population Group: Patients with Neuromuscular Disorders (NMDs).

Age Group: Adults, Elderly.

Population Details: Individuals suffering from conditions affecting the nervous system and sensory organs, and the musculoskeletal system.

Test Methodology: Self-administered questionnaire. Scoring is based on summing item responses, where higher scores indicate poorer quality of life or greater impact of the disease.

Keywords

Psychometrics, Neuromuscular disease, Health outcome, Clinical monitoring, Disability assessment, Symptom severity, Treatment efficacy.

Authors

Author ORCID Identifier: N/A (Information not provided in source.)

Affiliation Email addresses: N/A (Information not provided in source.)

Correspondence Address: N/A (Information not provided in source.)

Permissions & Fee and Test Year

The original scale was developed and published by Rose M, et al. in 2006. The subsequent Dutch adaptation was published by Seesing FM, et al. in 2015. Information regarding specific permissions and licensing fees for clinical or commercial use should be sought directly from the primary authors or the relevant publishing body. The explanatory form for the instrument is available online. The original PDF can be downloaded here: Toelichtingsformulier (Explanation Form).

Reference’s

Key references for the Individualized Neuromuscular Quality of Life Questionnaire (INQoL) include the original development and subsequent validation studies:

• Rose M, et al. (2006). Development and validation of the Individualized Neuromuscular Quality of Life Questionnaire (INQoL).
• Seesing FM, et al. (2015). Validation of the Dutch version of the Individualized Neuromuscular Quality of Life Questionnaire (INQoL).

Items of the Individualized Neuromuscular Quality of Life Questionnaire

IMPORTANT: The following scale items must be preserved in their original language and must not be changed in any way.

The specific 45 items comprising the Individualized Neuromuscular Quality of Life Questionnaire are proprietary or not publicly available in the source data provided. The items cover the three domains: Symptoms, Impact on specific life domains, and Treatment effects.